Why the study?
Heart failure has an increasing prevalence, significant morbidity, high mortality, and expanding healthcare costs, with rapidly evolving diagnostic and therapeutic modalities.
This review provides a comprehensive update on the current state-of-the-art management, diagnostic modalities, and future directions for heart failure.
Answers are grounded in this paper and cite their sources.
Provides clinicians a consolidated HF management reference; leaves open integration of novel diagnostics and therapies.
Heart failure (HF) is an important cardiovascular disease because of its increasing prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The number of HF patients is increasing worldwide, and Korea is no exception. There have been marked advances in definition, diagnostic modalities, and treatment of HF over the past four decades. There is continuing effort to improve risk stratification of HF using biomarkers, imaging and genetic testing. Newly developed medications and devices for HF have been widely adopted in clinical practice. Furthermore, definitive treatment for end-stage heart failure including left ventricular assist device and heart transplantation are rapidly evolving as well. This review summarizes the current state-of-the-art management for HF and the emerging diagnostic and therapeutic modalities to improve the outcome of HF patients.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: